Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MIR155 (MicroRNA 155)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

miR-155 overexpression	HER2 Positive Breast Cancer	miR-155 overexpression	HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3	trastuzumab Resistant: C3 – Early Trials trastuzumab Resistant : C3
miR-155 expression	HER2 Positive Breast Cancer	miR-155 expression	HER2 Positive Breast Cancer	letrozole Resistant: C3 – Early Trials letrozole Resistant : C3	letrozole Resistant: C3 – Early Trials letrozole Resistant : C3
miR-155 deletion + FLT3-ITD mutation	Acute Myelogenous Leukemia	miR-155 deletion + FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: D – Preclinical quizartinib Sensitive : D	quizartinib Sensitive: D – Preclinical quizartinib Sensitive : D
miR-155 overexpression	Diffuse Large B Cell Lymphoma	miR-155 overexpression	Diffuse Large B Cell Lymphoma	MRG-106 Sensitive: D – Preclinical MRG-106 Sensitive : D	MRG-106 Sensitive: D – Preclinical MRG-106 Sensitive : D
miR-155 underexpression	Renal Cell Carcinoma	miR-155 underexpression	Renal Cell Carcinoma	sunitinib Resistant: D – Preclinical sunitinib Resistant : D	sunitinib Resistant: D – Preclinical sunitinib Resistant : D
miR-155 expression	Thyroid Gland Carcinoma	miR-155 expression	Thyroid Gland Carcinoma	PLX4720 Resistant: D – Preclinical PLX4720 Resistant : D	PLX4720 Resistant: D – Preclinical PLX4720 Resistant : D
miR-155 expression	Pancreatic Cancer	miR-155 expression	Pancreatic Cancer	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D
miR-155 overexpression	Oral Cancer	miR-155 overexpression	Oral Cancer	cisplatin Resistant: D – Preclinical cisplatin Resistant : D	cisplatin Resistant: D – Preclinical cisplatin Resistant : D